As national elections loom, India’s prime minister has said the government will expand a retail scheme to sell cut-price no-name generic drugs intended to make medicines more affordable for the poor, and some analysts are expecting a potentially significant commercial impact on the country's main branded generics sector.
With campaigning for India’s general elections heading into its final stretch, Prime Minister Narendra Modi has announced the government will step up the roll-out of stores selling cheaper unbranded drugs as part of a push to “free poor people” from the worry of illness.
The government plans to increase the number of "Jan Aushadhi" or public medicine outlets to 7,500 by 2020, up from the
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy
